Literature DB >> 16024926

Eradication of Helicobacter pylori can be accurately confirmed 14 days after termination of triple therapy using a high-dose citric acid-based 13C urea breath test.

Haim Shirin1, Arie Levine, Orit Shevah, Vered Shabat-Sehayek, Hussein Aeed, Joram Wardi, Shlomo Birkenfeld, Rami Eliakim, Yona Avni.   

Abstract

BACKGROUND: Confirmation of Helicobacter pylori eradication by urea breath test (UBT) is currently performed 4-6 weeks after completion of therapy because of unacceptable false-negative results in UBTs performed earlier. Use of a high-dose citric acid test meal appears to enable accurate detection of H. pylori even during short term therapy with proton pump inhibitors. AIM: To evaluate if use of a high dose citric acid (4.0 g) test meal can decrease the interval required for confirmation of eradication after triple therapy.
METHODS: 233 patients positive for H. pylori were randomized to undergo UBT at 7 days or 14 days after triple therapy, and again at 6 weeks. The latter test was considered the gold standard test.
RESULTS: The UBT performed 6 weeks after the end of treatment found that 79.9% were cured. The same test 7 days after therapy found false-negative detection of H. pylori in 7.3% patients compared to 3.2% patients examined after 14 days. The sensitivity, specificity, positive and negative predictive values and accuracy for evaluation on day 14 were 80, 100, 100, 96.3 and 96.7%, respectively.
CONCLUSIONS: High-dose citric acid-based UBT is a valid test for the assessment of H. pylori status 14 days after triple therapy. This may obviate the delay in instituting second-line eradication therapy, or further evaluation of the symptomatic patient unresponsive to therapy despite eradication. Copyright (c) 2005 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16024926     DOI: 10.1159/000087045

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  6 in total

1.  Effect of Vonoprazan, a Potassium-Competitive Acid Blocker, on the 13C-Urea Breath Test in Helicobacter pylori-Positive Patients.

Authors:  Mayu Takimoto; Toshihiko Tomita; Takahisa Yamasaki; Shota Fukui; Masato Taki; Takuya Okugawa; Takashi Kondo; Tomoaki Kono; Katsuyuki Tozawa; Eitatsu Arai; Yoshio Ohda; Tadayuki Oshima; Hirokazu Fukui; Jiro Watari; Hiroto Miwa
Journal:  Dig Dis Sci       Date:  2017-01-12       Impact factor: 3.199

2.  Evaluation of methods for H. pylori detection in PPI consumption using culture, rapid urease test and smear examination.

Authors:  Farideh Siavoshi; Parastoo Saniee; Saman Khalili-Samani; Farideh Hosseini; Fahimeh Malakutikhah; Marzieh Mamivand; Somayeh Shahreza; Amir Houshang Sharifi
Journal:  Ann Transl Med       Date:  2015-01

3.  The diagnosis and management of H. pylori infection in Singapore.

Authors:  Claire Alexandra Zhen Chew; Tong Fong Lye; Daphne Ang; Tiing Leong Ang
Journal:  Singapore Med J       Date:  2017-05       Impact factor: 1.858

Review 4.  A review of Helicobacter pylori diagnosis, treatment, and methods to detect eradication.

Authors:  Elvira Garza-González; Guillermo Ignacio Perez-Perez; Héctor Jesús Maldonado-Garza; Francisco Javier Bosques-Padilla
Journal:  World J Gastroenterol       Date:  2014-02-14       Impact factor: 5.742

5.  Consensus on the clinical management, screening-to-treat, and surveillance of Helicobacter pylori infection to improve gastric cancer control on a nationwide scale.

Authors:  Bor-Shyang Sheu; Ming-Shiang Wu; Cheng-Tang Chiu; Jing-Chuan Lo; Deng-Chyang Wu; Jyh-Ming Liou; Chun-Ying Wu; Hsiu-Chi Cheng; Yi-Chia Lee; Ping-I Hsu; Chun-Chao Chang; Wei-Lun Chang; Jaw-Town Lin
Journal:  Helicobacter       Date:  2017-01-08       Impact factor: 5.753

Review 6.  Non-invasive diagnostic tests for Helicobacter pylori infection.

Authors:  Lawrence Mj Best; Yemisi Takwoingi; Sulman Siddique; Abiram Selladurai; Akash Gandhi; Benjamin Low; Mohammad Yaghoobi; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2018-03-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.